Moderna has announced its experimental vaccine against Covid-19 was shown to be 94.5% effective according to early results from a clinical trial with more than 30,000 participants.
“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent Covid-19 disease, including severe disease,” said Stephane Bancel, Moderna’s CEO.
According to Moderna, there have been 95 cases of Covid-19 confirmed in the trial, with 90 of those observed in the placebo group. There were 11 severe cases of the disease, with all 11 found in the placebo group.
The company said the vaccine was “generally well tolerated” and the majority of adverse events were mild or moderate in severity.